Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 2/20 | 0.57 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.57 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.57 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.57 |
| ▸ | ABL1 | P00519 | 1/20 | 0.57 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.56 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.51 |
| ▸ | MTOR | P42345 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2574304 | 0.85 | EPHX1 (0.61) | CHEK1NOTUM | |
| SCHEMBL2549205 | 0.83 | ABL1 (0.53) | PIK3CAMAPK8MAPK9MAPK10ABL1 | |
| SCHEMBL2319091 | 0.82 | NOTUM (0.56) | ABL1CHEK1NOTUMMTOR | |
| SCHEMBL2553716 | 0.81 | PIK3CA (0.52) | PIK3CAMAPK8MAPK9MAPK10 | |
| SCHEMBL2574821 | 0.81 | CHEK1 (0.52) | PIK3CAMAPK8MAPK9MAPK10CHEK1 | |
| SCHEMBL30600956 | 0.81 | MAPK1 (0.50) | PIK3CAMAPK8MAPK9MAPK10MAPK1 | |
| SCHEMBL20525170 | 0.81 | MAPK1 (0.47) | MAPK1 | |
| SCHEMBL2555222 | 0.81 | MAPK1 (0.50) | PIK3CAMAPK8MAPK9MAPK10MAPK1 | |
| SCHEMBL2547181 | 0.81 | MAPK1 (0.47) | PIK3CAMAPK8MAPK9MAPK10MAPK1 | |
| SCHEMBL2553789 | 0.81 | PIK3CA (0.46) | PIK3CAMAPK8MAPK9MAPK10ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8003662-B2 | Heterobicyclic thiophene compounds and methods of use | ARRAY BIOPHARMA, INC. (US) | 2011-08-23 | — | — | US | disclosed |
| US-20110130406-A1 | PYRAZOLO-PYRIDINES AS TYROSINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2011-06-02 | — | — | US | disclosed |
| US-20070197537-A1 | Heterobicyclic thiophene compounds and methods of use | ARRAY BIOPHARMA, INC. | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197537-A1 | Heterobicyclic thiophene compounds and methods of use | ERBB2, LCK, SRC | PIK3CA 539/4885MAPK8 734/4885MAPK9 645/4885 |
| US-20110130406-A1 | PYRAZOLO-PYRIDINES AS TYROSINE KINASE INHIBITORS | TYRO3, LCK, LTK | PIK3CA 371/4885MAPK8 220/4885MAPK9 195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.